Insmed Incorporated (INSM)

NASDAQ: INSM · IEX Real-Time Price · USD
76.71
-0.32 (-0.42%)
At close: Jul 12, 2024, 4:00 PM
76.97
+0.26 (0.34%)
After-hours: Jul 12, 2024, 7:05 PM EDT
-0.42%
Market Cap 12.37B
Revenue (ttm) 315.49M
Net Income (ttm) -746.89M
Shares Out 161.23M
EPS (ttm) -5.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,823,775
Open 77.00
Previous Close 77.03
Day's Range 75.57 - 77.93
52-Week Range 20.16 - 77.93
Beta 1.16
Analysts Strong Buy
Price Target 76.87 (+0.21%)
Earnings Date Aug 1, 2024

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2000
Employees 912
Stock Exchange NASDAQ
Ticker Symbol INSM
Full Company Profile

Financial Performance

In 2023, Insmed's revenue was $305.21 million, an increase of 24.39% compared to the previous year's $245.36 million. Losses were -$749.57 million, 55.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $76.87, which is an increase of 0.21% from the latest price.

Price Target
$76.87
(0.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , July 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

9 days ago - PRNewsWire

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and...

11 days ago - PRNewsWire

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

BRIDGEWATER, N.J. , June 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

17 days ago - PRNewsWire

Top 4 Health Care Stocks That May Keep You Up At Night This Month

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: APLTLLYTMDX
4 weeks ago - Benzinga

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

5 weeks ago - PRNewsWire

Insmed (INSM) CEO on the Company's Current Product Pipeline

Insmed (INSM) announced positive topline results from an Aspen Phase 3 study of Brensocatib. Insmed is a biopharmaceutical company that develops therapies for patients with serious and rare diseases.

5 weeks ago - Schwab Network

Insmed to Host Commercial Webinar on June 4, 2024

BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, w...

6 weeks ago - PRNewsWire

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

6 weeks ago - PRNewsWire

Insmed CEO on lung disease treatment and path forward

Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.

6 weeks ago - CNBC Television

Insmed Announces Proposed $500 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

6 weeks ago - PRNewsWire

Insmed Stock More Than Doubled in Value Tuesday—Here's Why

Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients wit...

6 weeks ago - Investopedia

Chart of the Day: Insmed

Michelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.

6 weeks ago - CNBC Television

Insmed stock doubles on positive ASPEN study results

Shares of Insmed Inc (NASDAQ: INSM) more than doubled on Tuesday after the biopharmaceutical firm reported positive results for its ASPEN study. Insmed stock soars on topline results from ASPEN study ...

6 weeks ago - Invezz

Insmed's stock rockets toward a 2-decade high after positive drug-trial data

Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positive P...

6 weeks ago - Market Watch

Insmed's lung disease drug succeeds in late-stage study

Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study, prompting its shares to double i...

6 weeks ago - Reuters

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Plac...

6 weeks ago - PRNewsWire

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J. , May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company o...

6 weeks ago - PRNewsWire

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Confe

—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the Q...

7 weeks ago - PRNewsWire

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positi...

2 months ago - PRNewsWire

Insmed To Present at the BofA Securities Health Care Conference 2024

BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

2 months ago - PRNewsWire

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

2 months ago - PRNewsWire

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to b...

3 months ago - PRNewsWire

Insmed To Present at Three March Conferences

BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

4 months ago - PRNewsWire

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling overlooked or unheard, in healthcare — — 5...

4 months ago - PRNewsWire

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study ...

5 months ago - PRNewsWire